Today they announced on conference call that they have started a Zika vaccine study. This is not a priority, but it can hopefully lend credibility to their platform if immunogenicity is robust.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.